Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (910)	1/22/2002 7:09:45 PM
From: tom pope	Read Replies (1) \| Respond to of 3044

16:44 ET Millennium Pharm (MLNM) 20.23 -0.17: Reports Q4 net loss of $0.23 per share, $0.04 worse than the consensus estimate; reports Q4 revenues of $54.6 mln versus the current consensus estimate of $55.4 mln; updates guidance for FY02; expects revenues of "more than $400 mln" versus the current consensus estimate of $373 mln; expects a net loss in the range of $175-$200 mln; expects to end the year with a cash balance in excess of $1.7 billion with approximately $250 million in long-term outstanding debt. Trying to buy a little after hours at 19.60, but not getting filled.

To: nigel bates who wrote (910)	1/22/2002 7:24:43 PM
From: software salesperson	Respond to of 3044

1/22/02 conference call notes 1. 2002 guidance 3-4 nmes in clinic, followed by 5 + in 2005 and thereafter integrilin growth 30% to 300m; mlnm gets 1/2 250m alliance revenue r&d 500 m nol 175-200 m cash 1.7 b + 250 m debt year-end 2. key 2001 accomplishments campath, mln341,mln02,mln977, 10 in clinic + 1 IND filed, 13 preclinical candidates, genomically derived mln4760, abbott, structural genomics,pharsight, 2000 druggable targets, >75 hts, in-licensing of 591, gcc, 576 3. 2002 goals build sustainable pipeline (i) 30% Integrilin increase + new indications (ii) mln341- - multiple myeloma + solid tumor in combination data 1st ½ (iii) 3-4 nmes in clinic (iv) > 75 hts (v) r&d 500 m personalized medicine and productivity- - pharmacogenomics in 6 clinical programs breakeven 2004 m&a and transforming alliances strong balance sheet 4. q&a (i) status of mln 341? - - 400-600 patients in p 3 multiple myeloma; data on mm and solid tumors in may at asco (ii) integrilin market share? - - now into mid 50%; market share data at aac meeting in march (iii) mln02 status?- -data later this year (iv) why increase in g&a ? - - building commercial capability (v) when receive campath revenues? - - 4 q each year (vi) affx collaboration?- - replacing internal platform for gene to patient with affx platform (vii) ’04 breakeven achievable? - - integrilin growth, possible 341 revenue, likely late stage products or products on the market m&a in oncology and cardio areas (viii) which are the 3-4 likeliest nmes? - - no direct answer; across entire portfolio (ix) rtk program?- - both corr and internal; ct53518 will enter clinic shortly; ct53608 for glioblastoma; large focus across all franchise areas (x) oral gp 11b-111a inhibitor status? - - unclear; waiting to observe competitive trial results; not a focus area (xi) mln977 status? - - has oral program; developing inhaled program for asthma (xii) acquire company vs. products? - - no direct answer (xiii) cardio trials are more expensive- is r&d estimate realistic?- - no answer. technical glitch ended the call prematurely 5. impression some focus on short term expenses as well as longer-term strategy. cardio seems like a good move. no real surprises sales